iCAD’s Strategic Partnership with Advanced Rad Solutions Expands Availability of the Xoft System into Dermatology Centers

  iCAD’s Strategic Partnership with Advanced Rad Solutions Expands
  Availability of the Xoft System into Dermatology Centers

Business Wire

NASHUA, N.H. -- September 11, 2013

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced a strategic
partnership with Advanced Rad Solutions (ARS) to place iCAD’s Xoft^® Axxent^®
Electronic Brachytherapy Systems^® at ARS sites to treat patients diagnosed
with non-melanoma skin cancer (NMSC). ARS is a full-service integrator of
radiation therapies into treatment centers and physician practices.

As part of the strategic partnership, the Xoft ^ System will be used at each
of ARS’ affiliated dermatology sites, beginning with its California sites,
allowing patients to undergo electronic brachytherapy treatment in the
convenience of a dermatologist’s office.

“We are pleased to provide patients with the most advanced treatment options
for skin cancer in one integrated setting,” said Ken Ferry, iCAD’s CEO. “Our
strategic partnership with ARS will enable us to treat more patients while
expanding the number of systems we have in place, ultimately improving patient

“Electronic brachytherapy is an advanced, non-invasive procedure that can now
be completed at the dermatologist’s office or in virtually any clinical
setting under the supervision of a radiation oncologist,” said Stephen
Doggett, M.D., Radiation Oncologist. “The on-site, real time collaboration of
the dermatologist and radiation oncologist both at the time of treatment
planning and in the treatment suite means improved outcomes and optimal
management of skin reactions. Patients are very pleased with this
multidisciplinary approach. By allowing providers and patients expanded access
to this proven treatment in their dermatologist’s office where they received
the diagnosis, there is a higher probability that patients will continue with
their course of treatment and ongoing care.”

“We believe this strategic partnership will change the way skin cancer
patients are treated by bringing the portable electronic brachytherapy
technology to the dermatologist’s office through collaboration with radiation
oncology,” said Steven Carrales, ARS President and CEO. “We now can offer
patients a non-invasive alternative with compelling clinical outcomes.
Additionally, by treating skin cancer patients in-house, we will reduce and
potentially eliminate the need for patients to see multiple physicians at
various locations, while ensuring that patients complete a full course of

ARS has affiliated dermatology customers in California, Arizona and
Washington, and has plans to expand to other states in the fourth quarter of
2013. Since June 2012, ARS customers have collectively treated more than 700
patients with the Xoft System.

About Non-Melanoma Skin Cancer
NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is
not only the most common type of skin cancer, it is the most common type of
cancer in humans. These cancers commonly appear on sun-exposed areas of the
body such as the face, ears, neck, lips, and backs of the hands. NMSC affects
approximately 2.2 million Americans each year.

About Advanced Rad Solutions
ARS is a full service integrator of radiation oncology services into physician
practices. ARS provides dermatologists with a comprehensive solution enabling
them to offer non-invasive, electronic brachytherapy skin cancer procedures
within their current physical offices. ARS’s full service approach results in
the seamless procurement and coordination of all necessary equipment,
dermatologists, radiation oncology medical professionals and technicians and
physicists in the setting of the dermatologist’s office. ARS has developed
several locations with affiliated dermatology customers across several states
in the western U.S.

About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S.
Food and Drug Administration and CE marked in the EU for use anywhere in the
body, including for the treatment of early stage breast cancer, endometrial
cancer, cervical cancer and skin cancer. It utilizes a proprietary
miniaturized x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and organs. Xoft is a
wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit

About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow solutions and
radiation therapies for the early identification and treatment of common
cancers. iCAD offers a comprehensive range of high-performance, upgradeable
CAD solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate cancers and
Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers
radiation treatment for early-stage breast cancer that can be administered in
the form of intraoperative radiation therapy or accelerated partial breast
irradiation. The Xoft System is also cleared for the treatment of non-melanoma
skin cancer, cervical cancer and endometrial cancer. For more information,
call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the Company’s
ability to identify a replacement for the Axxent FlexiShield Mini, the risks
relating to the Company’s acquisition of Xoft including, the expected benefits
of the acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at

Photos/Multimedia Gallery Available:



For iCAD
Kevin Burns, 937-431-7967
For iCAD investor relations
Anne Marie Fields, 212-838-3777 x6604
For iCAD media inquiries
Schwartz MSL
Helen Shik, 781-684-0770
For Advanced Rad Solutions
Alan Hughes, 317-439-2805
For Advanced Rad Solutions media inquiries
Robert Bonds, 956-789-8055
Press spacebar to pause and continue. Press esc to stop.